Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.

Sofía CarbajosaMaría Florencia PansaNatalia S PavioloAndrés M CastellaroDiego L AndinoAyelén D NigraIris Alejandra GarcíaAna C RaccaLucía Rodriguez-BerdiniVirginia AngioliniLaura GuantayFlorencia VillafañezMaría Belén FedericoMaría Celeste Rodríguez-BailiBeatriz L CaputtoGerard DrewesKevin P MadaussIsrael GlogerElmer FernandezGermán A GilJosé Luis BoccoVanesa Gottifredi Gastón Soria

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

We uncovered an unforeseen addiction of BRCA1-deficient cancer cells to PLK1 expression, which provides a new means to exploit the therapeutic potential of PLK1 inhibitors in clinical trials, by generating stratification schemes that consider this molecular trait in patient cohorts.

Keyphrases

clinical trial
poor prognosis
breast cancer risk
case report
wild type
genome wide
protein kinase
tyrosine kinase
binding protein
phase ii
gene expression
single molecule
phase iii